8 Nov 17

It really is absolutely critical for CMS to reconsider this decision, said Michael M. Graham, Ph.D., M.D., president of SNM and director of nuclear medicine at the University of Iowa Carver University of Medication in Iowa City. It really is unacceptable to possess reimbursement for only one scan if you want two to be able to assess efficacy of treatment. The letter–which was signed by the leadership of the National Oncologic Family pet Registry Functioning Group, the Academy of Molecular Imaging, the American University of Nuclear Medication, the American College of Radiology, the American Culture for Radiation Oncology, the Institute for Molecular Systems and SNM–presents CMS with three useful scenarios when a second initial FDG-PET scan would be necessary for optimal patient care.Prolia reduces the chance of fracture through a convenient injection given every six months. Amgen can be proud to create this new treatment available to doctors and their patients. Related StoriesCornell biomedical engineers develop 'super organic killer cells' to destroy malignancy cells in lymph nodesViralytics enters into scientific trial collaboration agreement with MSDMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic cancer patientsThe marketing authorization for Prolia comprises data from six Phase 3 trials, including two pivotal Phase 3 studies with fracture endpoints in the prostate and osteoporosis cancer tumor settings, which demonstrated that Prolia administered as a 60mg subcutaneous injection every six months decreases the incidence of fractures.